ALS Biopharma receives ADDF grant to build up therapeutics against Alzheimer’s disease The Alzheimer’s Medication Discovery Foundation announced today that it has awarded a grant of $195,000 to ALS Biopharma, LLC to build up therapeutics directed at clearing toxic proteins implicated in Alzheimer’s disease.This program will identify and develop small-molecule brain-penetrant inducers of heat shock protein 70 . Allen Reitz, CEO of ALS Biopharma . ‘We are excited to aid ALS Biopharma’s innovative program in this target region,’ said Howard Fillit, MD, Executive Director of the ADDF.’.

This evaluation of potential is usually complemented by an assessment of the background and standing of startups relative to their sector peers, allowing Crimson Herring to see past the ‘buzz’ and make the list a valuable device of discovery and advocacy for the most promising home based business models in North America. Related StoriesSurgical startup seeks funding to build virtual reality teaching libraryHealthcare technology sociable event of the entire year opens entriesRE.WORK showcases future technology and innovations in deep learning software’Choosing the companies with the strongest potential was by no means a little feat,’ said Alex Vieux, publisher and CEO of Red Herring.